Biotechnology company Ascletis Pharma Inc (HKEX:1672) on Wednesday reported promising topline pharmacokinetic data in a Phase Ib study of ASC30 oral once-daily tablet in participants with obesity.
The randomised, double-blind, placebo-controlled multiple ascending dose study was conducted in the United States. It demonstrated drug exposures (area under the curve over 0-24 hours or AUC0-24h) of 3,560 ng*h/mL and 5,060 ng*h/mL for cohort 1 (20 mg) and cohort 2 (40 mg), respectively, indicating that higher drug exposures are associated with greater weight loss.
The tablet was safe and well tolerated with no serious adverse events reported and no Grade 3 or higher adverse events (AEs) including GI-related AEs observed.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA